Atyr Pharma Inc

NASDAQ:LIFE  
8.74
-0.40 (-4.38%)
Products, Regulatory

Atyr Pharma Announces Positive Biomarker Data From Phase 2 Clinical Trial Of Atyr1923 Demonstrating Anti-Inflammatory Effects In Covid-19 Patients With Severe Respiratory Complications

Published: 03/15/2021 13:02 GMT
Atyr Pharma Inc (LIFE) - Atyr Pharma Announces Positive Biomarker Data From Phase 2 Clinical Trial of Atyr1923 Demonstrating Anti-inflammatory Effects in Covid-19 Patients With Severe Respiratory Complications.
Atyr Pharma - Atyr1923 Reduced Key Inflammatory Cytokines That Are Implicated in Sarcoidosis & Other Ilds, Consistent With Findings From Animal Models.
Atyr Pharma Inc - Patients Treated With Atyr1923 Demonstrated a Trend of Overall Improvement in Key Biomarkers Analyzed Compared to Placebo.